- Source : Press Release
- Date : 2021-11-24
- Event type : Marketed
- Companies : Celltrion, Inc.
Celltrion to Supply Covid-19 Treatment Regkirona to More Medical Facilities
Celltrion said Wednesday that it would supply Covid-19 antibody treatment, Regkirona (ingredient: regdanvimab), to more facilities treating patients with lighter symptoms to help curb its spread.
Celltrion plans to expand the supply of its Covid-19 antibody drug, Regkirona (ingredient: regdanvimab), to more medical facilities treating early-stage patients.
“Following the decision by Korea Disease Control and Prevention Center (KDCA) to expand the supply of Regkirona, we plan to expand the treatment's supply to Covid-19 treatment centers throughout the country, including nursing hospitals and community treatment centers (CTCs) on Wednesday,” the company said.
According to Celltrion, calls have been mounting for treating early-stage Covid-19 patients at CTCs. The company expects the expanded supply of Rekkona to reduce the number of patients with severe symptoms and ease the burden of operating sickbeds in state-designated hospitals.
Since it received conditional approval for Regkirona from the Ministry of Food and Drug Safety in February, Celltrion has supplied Regkirona to only designated medical institutions. However, according to the health authorities, the drug had been administered to 23,781 patients in 130 hospitals as of Nov. 18, showing the highest use among authorized Covid-19 treatments in the nation.
Researchers confirmed the safety and effectiveness of Regkirona in the global phase 3 clinical trials conducted on 1,315 patients mild and moderate Covid-19 patients in 13 countries, including Korea, the U.S., Spain, and Romania.
Regkirona showed similar efficacy and safety profile in analyzing a study comparing 330 patients with the Delta and other Covid-19 strains.
The drug obtained emergency use approval from the National Agency for Drug and Food Control of Indonesia (BPOM) in July and the Brazil National Health Surveillance Agency (ANVISA) a month after.
In November, Celltrion's antibody treatment for Covid-19 won full authorization from the European Medicines Agency.
"Celltrion expects the increased Regkirona supply will help reduce the morbidity of severe cases as the number of severe Covid-19 patients continued to rise since the government eased the Covid-19 policy," a Celltrion official said. We welcome the government's decision to increase supply to living treatment centers and nursing hospitals, and we will do our best to supply the treatment."